Telestroke-Guided Intravenous Tissue-Type Plasminogen Activator Treatment Achieves a Similar Clinical Outcome as Thrombolysis at a Comprehensive Stroke Center
Background and Purpose—Telestroke networks offer an opportunity to increase tissue-type plasminogen activator use in community hospitals.
Methods—We compared 83 patients treated with intravenous tissue-type plasminogen activator by telestroke to 59 patients treated after in-person evaluation by the same neurologists at a tertiary care stroke center. Onset and door-to-treatment times and functional outcome at 90 days were obtained prospectively. Favorable outcome was defined as modified Rankin Scale score ≤2.
Results—Favorable outcome rates were comparable between the groups (42.1% versus 37.5%, P=0.7). There was no significant difference in the rate of symptomatic hemorrhage.
Conclusions—Telestroke is a viable alternative to in-person evaluation when stroke expertise is not readily available.
- Received May 7, 2011.
- Accepted May 27, 2011.
- © 2011 American Heart Association, Inc.